

May 2025 Release Notes

Version 3.50.1

Dose calculation for drugs with maximum parameters

Starting **Thursday, May 22, 2025, at 8:30 p.m. CDT**, iKnowMed will apply a maximum parameter to the calculation of formula order doses for applicable drugs.

This update will help reduce the risk of dosing error for patients who exceed the parameter identified in the drug's clinical guidance.

What's changing

The following drugs will be updated with the parameters listed below.

Drug	Maximum Parameter
Carfilzomib IV	BSA: 2.2 m2
Ixabepilone IV	BSA: 2.2 m2
Brentuximab Vedotin IV	Weight: 100 kg
Tisotumab Vedotin-tftv IV	Weight: 100 kg
Enfortumab Vedotin-ejfv IV	Weight: 100 kg
Datopotamab Deruxtecan-dlnk IV	Weight: 90 kg

New regimen orders

New regimen orders entered after the content release will function as follows:

- When a cap value is applied to the calculation of the order dose, “[cap value] used” displays for the order (see callout 1, for example). This information displays for the order where formula dose order details are present including:
 - Regimen draft order list
 - Order editor
 - Adjust Dose modal of the order editor
 - Order cart
 - Order detail dialog
 - Hover on the order Flowsheet cell
 - Interval Summary Active Regimen details
 - Order History Regimen details
 - Orders Queue entry
 - Admix entry
 - Ins. Auth/Fin. Counseling Worklist Queue entry
 - Printed reports that include formula dose order details

Flowsheet ▼ This Display is Filtered i Find:

	4/25/25 (Fri)	4/26/25 (Sat)	4/27/25 (Sun)
▼ Brentuximab vedotin + AVD D1,15 Q28D	C1D1	C1D2	
▼ CHEMOTHERAPY			
◀ Doxorubicin IV Σ	57 mg (25 mg/m2)		
◀ Vinblastine IV	14 mg (6 mg/m2)		
◀ Dacarbazine IV	860 mg (375 mg/m2)		
▼ IMMUNOTHERAPY			
◀ Brentuximab Vedotin IV	120 mg (1.2 mg/kg)		
▶ ADDITIONAL MEDICATIONS	1	Brentuximab Vedotin IV 120 mg (1.2 mg/kg); Weight: 113.4 kg; 100 kg used = 120 mg) Brentuximab Vedotin IV 50 mg recon soln 120 mg intravenously Piggyback once. Admin over: 30 minutes Instructions: Max Dose 120 mg (based on max weight 100 kg). Dilute in a minimum of 100 mL D5W, NS or LR to achieve a final concentration of 0.4 to 1.8 mg/mL. Do not mix or administer with other drugs. Brentuximab vedotin is an irritant.	
▶ PREMEDICATIONS			
▶ **PRN** HYPERSENSITIVITY MEDS			
▼ Medications			
▼ In-House			
◀ datopotamab deruxtecan-dlnk IV			
▼ Services			

- The “[cap value] used” information is shown in red in the Regimen draft order list, the Adjust dose modal of the order editor, the order detail dialog, in the cart for the order if entered as a non-regimen order, Order History Regimen details,

Interval Summary Active Regimens details, and the Ins. Auth/Fin. Counseling Worklist Queue entry (see callout 2, for example).

Regimen Name	Dose	Calculated Dose	Schedule
CHEMOTHERAPY			
Doxorubicin IV 57 mg (25 mg/m²; BSA: 2.28 m² = 57 mg) Doxorubicin IV 57 mg intravenously Push once. Admin over: 5 minutes to 10 minutes. Instructions: Doxorubicin is a vesicant.	25 mg/m ²	57 mg	C1D1,C1D15,C2D1,C2D15,C3D1,C3D15,C4D1,C4D15...
Vinblastine IV 14 mg (6 mg/m²; BSA: 2.28 m² = 14 mg) Vinblastine IV 14 mg intravenously Piggyback once. Admin over: 5 minutes to 15 minutes. Admix fluid: 0.9 % Sodium Chloride Volume: 50 mL. Instructions: Final admixture containing vinblastine must be labeled: "FATAL IF GIVEN INTRATHECALLY. FOR IV USE ONLY." Vinblastine is a vesicant.	6 mg/m ²	14 mg	C1D1,C1D15,C2D1,C2D15,C3D1,C3D15,C4D1,C4D15...
Dacarbazine IV 860 mg (375 mg/m²; BSA: 2.28 m² = 860 mg) Dacarbazine IV 860 mg intravenously Piggyback once. Admin over: 30 minutes to 60 minutes Volume: 250 mL to 500 mL. Instructions: Dilute in 250-500 mL D5W or NS. Rapid infusion may cause venous irritation. If venous irritation occurs, slow the rate of infusion. Protect from light. Dacarbazine is an irritant.	375 mg/m ²	860 mg	C1D1,C1D15,C2D1,C2D15,C3D1,C3D15,C4D1,C4D15...
IMMUNOTHERAPY			
Brentuximab Vedotin IV 120 mg (1.2 mg/kg; Weight: 113.4 kg; 100 kg used = 120 mg) Brentuximab Vedotin IV 50 mg recon soln 120 mg intravenously Piggyback once. Admin over: 30 minutes. Instructions: Max Dose 120 mg (based on max weight 100 kg). Dilute in a minimum of 100 mL D5W, NS or LR to achieve a final concentration of 0.4 to 1.8 mg/mL. Do not mix or administer with other drugs. Brentuximab vedotin is an irritant.	1.2 mg/kg	120 mg	C1D1,C1D15,C2D1,C2D15,C3D1,C3D15,C4D1,C4D15...
ADDITIONAL MEDICATIONS			
Nyvepria (Pegfilgrastim-aptf Subcutaneous) Nyvepria (Pegfilgrastim-aptf Subcutaneous) 6 mg/0.6 mL syringe 6 mg subcutaneously once. Instructions: Administer once per cycle at least 24 hours after and 14 days before chemotherapy. NOTE: This is Nyvepria.	6 mg		C1D2,C1D16,C2D2,C2D16,C3D2,C3D16,C4D2,C4D16...
<input type="checkbox"/> Udenyca (Pegfilgrastim-cbqv Subcutaneous) Udenyca (Pegfilgrastim-cbqv Subcutaneous) 6 mg/0.6 mL syringe 6 mg subcutaneously once. Instructions: Administer once per cycle at least 24 hours after and 14 days before chemotherapy. NOTE: This is Udenyca.	6 mg		C1D2,C1D16,C2D2,C2D16,C3D2,C3D16,C4D2,C4D16...
<input type="checkbox"/> Udenyca Onbody (pegfilgrastim-cbqv Subcutaneous (via wearable injector)) Udenyca Onbody (pegfilgrastim-cbqv Subcutaneous (via wearable injector)) 6 mg/0.6 mL syringe, w/ wearable injector 6 mg subcutaneously using wearable injector once. Instructions: May be applied by a healthcare professional on the same day as chemotherapy or the last day of chemotherapy in a multi-day regimen using only the co-packaged pegfilgrastim-cbqv. The device must be applied to patient's skin (abdomen or back of arm). Usually applied to the abdomen, the back of arm should only be used if there is a caregiver available to monitor the injector. Pegfilgrastim-cbqv will begin infusing approximately 27 hours later and deliver pegfilgrastim-cbqv over 5 minutes. NOTE: This is Udenyca.	6 mg		C1D1,C1D15,C2D1,C2D15,C3D1,C3D15,C4D1,C4D15...

- When a patient experiences a weight change during an active regimen, the existing weight change alert configuration in Practice Preferences will continue to operate based on the selected threshold setting.

NOTE: The weight change alert will be triggered even if there is no alteration in the calculated dose.

- When users view the patient’s recorded weight or BSA values for two dates within the Adjust Dose modal, the cap value will be displayed if it has been applied to the calculated dose.

Brentuximab Vedotin IV, 117 mg (1.2 mg/kg; Weight: 97.52 kg = 117 mg) on 04/25/2025 (Status: *Electronically signed*)... required

Rx Formula Dose QUICK SIG PICK SHOW DRUG FORMS

Dose Unit
 1.2 mg/kg ADJUST DOSE

1.2 mg/kg, 97.52 kg Weight = 117 mg.

Brentuximab Vedotin IV, 50 mg recon soln. 117 mg intravenously Piggyback Dilute in a minimum of 100 mL D5W, NS or LR to achieve a final co...

Generic

Dose	Unit	Form
117	mg	50 mg recon soln
Route	Method	Frequency
intravenously	Piggyback	once
<input type="checkbox"/> PRN		
Administer Over		
30	minutes	
Admix Fluid		
Select		Volume
Instructions <input type="checkbox"/> Instructions replace required fields Max Dose 120 mg (based on max weight 100 kg). Dilute in a minimum of 100 mL D5W, NS or LR		
		Duration

Dose Calculator/Formula Amount/Adjust

Current Dose: 1.2 mg/kg 117 mg

Dose Amount/Unit * Percentage change

1.2 mg/kg Select Select %

Recalculate using weight:

97.52 kg - 04/14/2025
 101.15 kg **100 kg used** - 04/25/2025

Calculated Result: 120 mg

Adjusted Amount: mg

CALCULATE
 UPDATE ORDER
 CANCEL

Schedule Info

Note: Any approved cycle days will not be impacted.

Change for:
 This day only
 This day to end of cycle
 This day to end of regimen
 Click the edit button to modify the order schedule.

Add/Remove Days: Apply details to all days EDIT

Preview of changes: C1D1, C1D15, C2D1, C2D15, C3D1, C3D15, C4D1, C4D15, C5D1, C5D15, C6D1, C6D15

SIGN & SAVE
 CLOSE

Existing regimen orders

Important: Existing patient regimen orders with the above-listed drugs must be edited for the new functionality to apply to the patient's regimen orders going forward. To update active patient regimen orders:

1. Open the patient's chart and navigate to the **Flowsheet**.
2. Locate the regimen in the patient's flowsheet and click on the order in the cell.
3. Select the option to **Edit regimen order** (callout 1).

Ixabepilone IV required

Options for Occurrence

- Print
- 1 Edit Regimen Order**
- Audit History

Ixabepilone IV 89 mg (40 mg/m2; BSA: 2.23 m2 = 89 mg)

Ixabepilone IV

89 mg intravenously Piggyback once. **Instructions:** Dilute in LR or NS based on final concentration between 0.2 - 0.6 mg/mL. When using a 250 mL or a 500 mL bag of 0.9% Sodium Chloride Injection to prepare the infusion, the pH must be adjusted to a pH between 6.0 and 9.0 by adding 2 mEq (ie, 2 mL of an 8.4% w/v solution or 4 mL of a 4.2% w/v solution) of Sodium Bicarbonate Injection, prior to the addition of the constituted IXEMPRA solution. Infuse using an in-line filter. Infusion container and tubing must be DEHP free. Observe patient for hypersensitivity reaction.

CLOSE

4. In the order editor, select the **QUICK SIG PICK** button (callout 2).
5. View the available dose options that include an override setting.
6. Select the SIG with the appropriate dose for the order (callout 3).

Ixabepilone IV, 89 mg (40 mg/m2; BSA: 2.23 m2 = 89 mg) on 07/01/2025 (Status: Electronically signed) : C4D1 required

Rx Formula Dose **2 QUICK SIG PICK** SHOW DRUG FORMS

Dose **Unit** mg/m2

40 mg/m2, 2.23 m2 BSA

- Ixabepilone 24 mg/m2 intravenously Piggyback every 3 weeks (SIG contains dose override setting)
- Ixabepilone 24 mg/m2 intravenously Piggyback once (SIG contains dose override setting)
- Ixabepilone 40 mg/m2 intravenously Piggyback once (SIG contains dose override setting)** **3**
- Ixabepilone 32 mg/m2 intravenously Piggyback every 3 weeks (SIG contains dose override setting)
- Ixabepilone 32 mg/m2 intravenously Piggyback once (SIG contains dose override setting)
- Ixabepilone 40 mg/m2 intravenously Piggyback every 3 weeks (SIG contains dose override setting)
- Ixabepilone 40 mg/m2 intravenously Piggyback once (SIG contains dose override setting)

Dose **Unit** mg

Route Intravenously **Method** Piggyback **Frequency** once PRN

Administer Over

Admix Fluid **Volume** mL

Instructions Instructions replace required fields
 Dilute in LR or NS based on final concentration between 0.2 - 0.6 mg/mL. When using a 250 mL or a 500 mL bag of 0.9% Sodium Chlorid...

Duration

Schedule Info
 Note: Any approved cycle days will not be impacted.
Change for: This day only This day to end of cycle This day to end of regimen [Click the edit button to modify the order schedule.](#)
Add/Remove Days: Apply details to all days [EDIT](#)
 Preview of changes:C1D1,C2D1,C3D1,C4D1,C5D1,C6D1,C7D1,C8D1

SIGN & SAVE **CLOSE**

7. For patients with a BSA or Weight that exceeds the cap, the calculated dose will be updated, and use of the cap value will display in the order editor (callouts 4-5).
8. Select the schedule for the order (e.g., This day to the end of regimen).
9. Sign and save or save the regimen order editor.

Ixabepilone IV, 88 mg (40 mg/m2; BSA: 2.23 m2; 2.2 m2 used = 88 mg) on 07/01/2025 (Status: Electronically signed) ... required

4

Rx Formula Dose QUICK SIG PICK SHOW DRUG FORMS

Dose Unit
40 mg/m2 ADJUST DOSE

5

40 mg/m2, 2.23 m2 BSA - 2.2 m2 Used BSA = 88 mg.

Ixabepilone IV, 88 mg .88 mg intravenously Piggyback once . Dilute in LR or NS based on final concentration between 0.2 - 0.6 mg/mL. When using a 250 mL or a 500 mL bag of 0.9% Sodium Chlorid...

Dose Unit Form
88 mg Select

Route Method Frequency
intravenously Piggyback once PRN

Administer Over
Select

Admix Fluid Volume
Select mL

Instructions Instructions replace required fields
Dilute in LR or NS based on final concentration between 0.2 - 0.6 mg/mL. When using a 250 mL or a 500 mL bag of

Duration
Select

Schedule Info
Note: Any approved cycle days will not be impacted.
Change for: This day only This day to end of cycle This day to end of regimen Click the edit button to modify the order schedule.
Add/Remove Days: Apply details to all days EDIT
Preview of changes:C4D1,C5D1,C6D1,C7D1,C8D1

SIGN & SAVE CLOSE

Completion of these steps is required for this feature to take effect on active patient regimens. The added functionality will not be applied to the dose calculation of future orders in active regimens without this update.

Impact to custom regimens

If your practice has created a custom regimen template with a drug listed above (including a custom version of the drug), an update to the regimen template is necessary to leverage this feature.

Users with **Manage > Regimen Templates** permissions must update the applicable orders in each of the impacted regimen templates following the content release on May 22, 2025, as follows:

1. Open the regimen template.
2. Click on the order that requires the BSA or Weight parameter (callout 1).

Ashley's Dashboard | Regimen Templates x | Research Ixabepilone D1 Q21D x

SAVE SAVE AND INCREMENT VERSION COPY REGIMEN RESET PRINT **Note: Changes to Regimen Details, Preference, Cycles, and Patient Education sections must be Saved before**

Regimen Items

Note: Changes in this section are automatically saved.
Medication, Imaging, Lab, Services

C / P	Pre-Check	Name		1	2	3	4	5	6	7	8	9	10	11	12
			CHEMOTHERAPY												
	<input checked="" type="checkbox"/>		BMS-247550 invest IV 40 mg/m2 BMS-247550 invest IV intravenously once. Instru...												
			PREMEDICATIONS												
		<input checked="" type="checkbox"/>	Granisetron IV Granisetron IV 1000 mcg intravenously once.												
			Granisetron Oral Granisetron Oral 1 mg tablet 2 mg orally every day.												
			[Rx] Granisetron Oral Granisetron Oral 1 mg tablet 2 tablet orally every day as ...												
			Ondansetron IV Ondansetron IV 8 mg intravenously once.												

- In the order editor, click the **QUICK SIG PICK** button to view available dose options that include the BSA or Weight cap (callout 2).
- Choose the SIG with the correct dose for the order in the template (callout 3).
- Click **SAVE** in the order editor (callout 4).

BMS-247550 invest IV, 40 mg/m2 required

Rx Formula Dose **QUICK SIG PICK** SHOW DRUG FORMS Research Option: --Please Select--

Dose **Unit** **Unit**

40 mg/m2 40 mg/m2 intravenously once (SIG contains dose override setting) **3**
 50 mg/m2 intravenously once (SIG contains dose override setting)

BMS-247550 invest IV, intravenously once . Use non-PVC tubing. Infuse over 3 hours. Infuse in Lactated Ringers at a final concentration of 0.2mg/mL to 0.6 mg/mL. U... x

Dose **Unit** **Form**

Route **Method** **Frequency**

intravenously Select once PRN

Administer Over

Admix Fluid **Volume**

Select mL

Instructions Instructions replace required fields

Use non-PVC tubing. Infuse over 3 hours. Infuse in Lactated Ringers at a final concentration of 0.2mg/mL to 0.6 mg/mL.

Allow substitutions. **Duration**

Do Not Bill Drug Do Not Bill Administration

4 SAVE CANCEL

- When all applicable orders in the template have been updated, click **SAVE** or **SAVE AND INCREMENT VERSION** in the regimen template to include configuration with the BSA or Weight cap for new regimen orders (callouts 5-6).

Ashley's Dashboard | Regimen Templates × | Research Ixabepilone D1 Q21D ×

SAVE SAVE AND INCREMENT VERSION COPY REGIMEN RESET PRINT **Note: Changes to Regimen Details, Preference, Cycles, and Patient Education sections must be Saved before**

5 6

Regimen Items

Note: Changes in this section are automatically saved.
Medication, Imaging, Lab, Services

C / P	Pre-Check	Name		1	2	3	4	5	6	7	8	9	10	11	12
			CHEMOTHERAPY												
	<input checked="" type="checkbox"/>		BMS-247550 invest IV 40 mg/m2 BMS-247550 invest IV intravenously once. Instru...												
			PREMEDICATIONS												
		<input checked="" type="checkbox"/>	Granisetrone IV Granisetron IV 1000 mcg intravenously once.												
			Granisetrone Oral Granisetron Oral 1 mg tablet 2 mg orally every day.												
			[Rx] Granisetron Oral Granisetron Oral 1 mg tablet 2 tablet orally every day as ...												
			Ondansetron IV Ondansetron IV 8 mg intravenously once.												

When to submit a ServiceNow ticket

- If the dose required for the regimen template is not available in a SIG for the drug, submit a ServiceNow ticket to request it.
- To request the maximum parameter configuration for a new drug, submit a ServiceNow ticket.

Expanded PDMP access for all Schedule II–IV drugs

The Prescription Drug Monitoring Program (PDMP) feature will be expanded to provide greater visibility into patients’ controlled substance histories.

What’s changing

Previously, PDMP reports were limited to Schedule II–IV opioids. With this update, the feature now encompasses all Schedule II–IV drugs, covering both opioid and non-opioid medications for initial prescriptions and renewals.

Practices with PDMP integration

When prescribing a Schedule II, III, or IV medication, a "View Report" button will appear within the PDMP section of the order details window (callout 1) and a "View PDMP Report" button will appear on the Medications page of the patient's chart (callout 2). This functionality is available for practices integrated with their State PDMP through Bamboo Health or Logicoy.

By clicking this button, healthcare professionals can review the patient's history with controlled substances and evaluate any potential risk of overdose prior to finalizing the prescription.

05/01/2025 Ativan (Lorazepam Oral), 1 mg tablet required

1 Error
1. Prescribing Location must be selected

Characters used: 32 (Max for eRx=140)
 Allow substitutions.

Dispense: 30 Unit: Tablet Refills: 0 Duration: days

Do Not Bill Drug Do Not Bill Administration Prior Authorization #

Prescription Drug Monitoring Program (PDMP)

If available, you can view the patient's PDMP report. PDMP querying is applicable for MIPS PI when prescribing controlled substances.

1 **VIEW REPORT** I have checked my state or local PDMP controlled substances database for this patient
PDMP Report Last Reviewed: 04/22/2025 08:34 AM

Location, Chart Comments and Problems

Fill Method: eRx Print Rx - local form printer Prescribe only - no print

Does not appear on Rx Chart Comments

Associated problems Create a new problem

- Colon cancer * (C18.0 Malignant neoplasm of cecum)
- Non-small cell lung cancer (disorder)
- Primary malignant neoplasm of prostate (disorder) (C7A.8)
- Other malignant neuroendocrine tumors

OK CANCEL NEXT ORDER

Chart Summary **Clinical Profile** Flowsheet Orders Results Documents Demographics Nursing Care Scheduler Admix Charge Capture Messages **DECISION TOOLS**

Problems Treatments Chart Alerts Care Plan **Medications** Allergies Health Maintenance Observations Family Hx OB/GYN Hx Devices Patient Hx

Cumulative Drug Dose **0** **ADD OFFSITE DRUG DOSE**

Name	Offsite Dose	Dose Given	Total (Offsite Dose + Given)	Total Ordered Dose (Not Given)	Projected Total Dose	Recommended Max Lifetime Dose	Alert
No Results Found							

Medication List **10** **ADD EXTERNAL MED** No Known External Medications **2**

VERIFY INACTIVATE Active Pending Inactive Removed **SHOW RX HX** **RECONCILE ELECTRONICALLY** **RECONCILED ...** **VIEW PDMP REPORT**

Type/Description	Start	End	Status	Inactivated/Verification Info	Inactivated/Verification Hx
Prescriptions					
<input type="checkbox"/> Alorazepam Oral 0.5 mg tablet 1 tablet orally 2 times per day as needed for anxiety	04/09/2025	--	Active		i
<input type="checkbox"/> Benzphetamine 50 mg tablet 1 tablet orally daily	04/07/2025	--	Active		i
<input type="checkbox"/> Carisoprodol-ASA-Codine Oral 200-325-16 mg tablet 1 tab orally 3 times per day	04/06/2025	--	Active		i

Practices not integrated with PDMP

For practices that are not integrated with Bamboo Health or Logicoy, the process remains straightforward while ensuring compliance. A **“PDMP reviewed”** checkbox will be clearly displayed, allowing users to manually select or deselect it (callout 3).

This action signifies that you reviewed the pertinent information regarding the patient's history with controlled substances.

04/09/2025 Alprazolam Oral, 0.5 mg tablet

1 Error
1. Prescribing Location must be selected

pat new 38/F MRN:pat_vbc DOB:01/01/ Addr: n/a, n/a, n/a n/a Ph: n/a

Rx Formula Dose [QUICK SIG PICK](#) [SHOW DRUG FORMS](#)

Rx Alprazolam Oral, 0.5 mg tablet. 1 tablet orally 2 times per day prn anxiety . Dispense 60 Tablet. Refills: 0
Generic S4

Form	Dose	Unit		
0.5 mg tablet	1	tablet		
Route	Frequency			
orally	2 times per day	<input checked="" type="checkbox"/> PRN Reason for order anxiety		
Instructions		Instructions to Pharmacist		
<input type="checkbox"/> Instructions replace required fields				
<small>Characters used: 54 (Max for eRx=140)</small>				
<input checked="" type="checkbox"/> Allow substitutions.				
Dispense	Unit	Refills	Duration	
60	Tablet	0	30 days	
<input type="checkbox"/> Do Not Bill Drug		<input type="checkbox"/> Do Not Bill Administration		Prior Authorization #
3 <input type="checkbox"/> PDMP reviewed				

Location, Chart Comments and Problems

Fill Method	Does not appear on Rx	Associated problems Create a new problem
	Chart Comments	<input checked="" type="checkbox"/> Family history of cancer of the brain * (Z85.038 Personal history of other malignant neoplasm of large intestine)

Why this matters

Improved Patient Safety: Your practice can now see a more complete picture of a patient’s medication history across all relevant controlled substances, helping to avoid duplicate therapies and identify potential misuse.

MIPS Compliance Support: This expansion helps practices participating in the Merit-based Incentive Payment System (MIPS) meet the requirements for the **Query of PDMP measure**, part of the Promoting Interoperability performance category.

Additional Enhancements (A-Z)

Admin > Electronic Case Reporting

Previously, patient visits without a specified human resource (such as lab or infusion appointments) were excluded from electronic case reporting. With this enhancement, all visit types will be reported.

The Electronic Case Reporting page will also include an **"Appointment Resource"** column (previously titled, "Appointment Provider") to display the name of the provider if the patient meets with a provider or the appointment type (e.g., Laboratory Test) if the patient’s visit does not involve a human resource.

Patients with multiple visits involving different resources might appear more than once in the table, ensuring all aspects of patient care are accurately represented.

Fixes (A-Z)

Worlist Queues > Orders Queue

Some users reported that order statuses were inadvertently lost in the Orders Queue if they were also updated in the Orders I/F queue. This has been corrected, and Orders will now reliably retain their status, whether they are updated in the Orders I/F queue or directly in the Orders Queue. This ensures that all updates are accurately reflected, maintaining the integrity of your workflow.